JAIME ALMANDOZ: Open Payments
NPI 1215060876 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$194,176 in 137 payments from 10 companies in 2025. Trend: 2023 $38,818 · 2024 $66,067 · 2025 $194,176
Consulting: $100,161Travel & lodging: $71,126Speaker / faculty: $18,420Food & beverage: $3,301Honoraria: $1,071Education: $97
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim International GmbH | 37 | $62,069 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 33 | $46,544 |
| Eli Lilly and Company | 27 | $27,683 |
| Amgen Inc. | 10 | $24,419 |
| Novo Nordisk AS | 12 | $16,633 |
| Novo Nordisk Inc | 10 | $8,637 |
| ABBVIE INC. | 2 | $4,650 |
| Lilly USA, LLC | 3 | $2,387 |
| Rhythm Pharmaceuticals, Inc. | 1 | $1,071 |
| Perspectum Diagnostics Ltd | 2 | $81 |
Products named: ZEPBOUND, MOUNJARO, Wegovy, KISUNLA, TEPEZZA.
Industry payments across TX — which companies pay providers there.
